SmartTRAK provides insights into the latest trends, research and consensus opinions in surgical Orthobiologic treatments and non-operative regenerative medicine from this year’s BA Summit and AANA meetings.
2 min read
BA Summit and AANA Join Forces to Share Orthobiologic Insights
By David Shepard on 7/8/25 9:30 AM
3 min read
Anika Therapeutics: Innovations in Early Orthopedic Interventions
By Freddy Buntoum on 6/23/25 10:03 AM
Dr Cheryl Blanchard, president and CEO of Anika Therapeutics, discusses the company, technology and developments for future growth in an interview with SmartTRAK.
In a recent interview with SmartTRAK, Dr. Cheryl Blanchard, president and CEO of Anika Therapeutics, discussed the company’s strategic direction, proprietary technology and advancements in its next-generation osteoarthritis (OA) pain management and regenerative solutions.
To find out more about the company, its differentiated technologies, products and growth strategy, click on the following video (26:40 min).
Interview topics by timecode are provided below, as is a link to download a complete transcript of the interview.
Interview Outline by Timecode:
00:20 Introduction to Anika Therapeutics, president and CEO Dr. Cheryl Blanchard and the company’s strategy.
01:14 The US OA Injectables Market and Anika’s next-generation OA pain solution, Cingal.
02:52 Cingal’s advantages and how it fit in the treatment continuum.
04:56 Cingal’s positioning and clinical trials’ progress.
10:47 Marketing communication, commercial and pricing approach and beyond knee OA.
13:42 Hyalofast, Anika’s next-generation cartilage repair solution.
17:25 Anika’s regenerative platform and the Integrity Implant System.
19:54 Cheryl Blanchard’s take on the next major disruptive force.
22:42 Thoughts around healthcare policy changes, tariffs uncertainty and other macro trends.
Click the button below to download and read the complete transcript of SmartTRAK's interview with Dr. Cheryl Blanchard, president and CEO of Anika Therapeutics, conducted by Freddy Buntoum, SmartTRAK Senior Analyst, Orthobiologics and Regenerative Medicine.
3 min read
Aatru Medical: Next-Gen NPWT for Surgical Incisions
By David Shepard on 6/3/25 9:30 AM
Thomas Lash, COO and co-founder of Aatru Medical, talks about the company’s innovative single-use negative pressure device, NP-Sims, a Negative Pressure Surgical Incision Management System.
Thomas Lash, chief operating officer and co-founder of Aatru Medical elaborates on the company’s strategy to mitigate the risk of surgical site infections through NP-SIMS, their single-use negative pressure surgical incision management system. To listen to the interview, please click on the following video (21:21 minutes). A link to download a complete transcript of the interview is provided below.
SmartTRAK: Hi, this is David Shepard, senior analyst with SmartTRAK. Today it's my pleasure to be joined by Tom Lash, COO and co-founder of Aatru. He's going to talk to us today about a product that he co-invented, called NPSims. Tom, tell us a little about your company and about the product.
Tom Lash: We started the business about eight years ago, a small research and commercialization team with the goal of developing an alternative solution for the single-use, disposable negative pressure wound therapy market. Kind of a mouthful to say that, but in essence, what we were trying to do is looking at the predicate devices that are on the market, we knew that if we were going to try and have a product that could make an impact on that market segment, it would be necessary for us to find an innovative mode of action to create the negative pressure without the current use of electromechanical pump which powers the leading products that are in use today. They have an electromechanical pump. They're battery-operated. They have software. Those products were primarily devised for the open or chronic wound market, and because of our focus on the surgical incision market, we were able to design something that was different. We believe the current products are probably over-engineered for the surgical incision market. So, our approach was to devise ...
Click the button below to download and read the complete transcript of SmartTRAK's interview with Aatru Medical's Co-Founder and COO Thomas Lash, conducted by David Shepard, SmartTRAK Lead Analyst, Orthobio & Regen.
3 min read
CG 2025 Musculoskeletal Conference: Spotlight on Doron Therapeutics
By Sharon O'Reilly on 3/11/25 11:40 AM
SmartTRAK spotlights Doron Therapeutics in an interview with CEO Alessandra Pavesio at CG 2025 Musculoskeletal Conference in San Diego.
To find out more, watch the following video (4:27 min). A link to a transcript of the interview is also provided below.
SmartTRAK: Hi, this is Sharon O'Reilly. I'm at the Canaccord Conference before the 2025 AAOS, and I ran into Alessandra Pavesio, who's so excited about her company, Doron Therapeutics.
So, Alessandra, why don't you tell us a little bit about the company and some of the exciting new developments.
Alessandra Pavesio: It's always great to see you, Sharon. I love bumping into you and having some really good news to deliver. First of all, what is Doron Therapeutics? It's a management-led spin-off. We really were passionate about a technology that we've developed with Bioventus, and when Bioventus divested from this program for financial considerations, we were able to negotiate a very favorable deal to actually set up a spin-off company and go raise private capital to invest in the program.
The good news is that, yes, we've set up a company. Yes, we have raised private capital. And so now we are really up and running and getting ready to start a Phase III study.
Big milestone that we've accomplished is that we've been recognized by FDA as an RMAT therapy. RMAT means Regenerative Medicine Advanced Therapy. As such, that means attention from senior officials at FDA that are really partnering with you to get this product to market for the patients that we serve. Super excited.
SmartTRAK: Tell us about the product.
AP: So our lead program is called MOTYS. It's placental-derived injectable therapeutic. It's a biological drug that ...
Click the button below to download and read the complete transcript of SmartTRAK's interview with Doron Therpeutics' CEO Alessandro Pavesio, conducted by Sharon O'Reilly, SmartTRAK Founder and CEO.
4 min read
SmartTRAK's Top Blog Posts of 2024
By Thomas Wallick on 1/21/25 9:30 AM
In 2024, SmartTRAK continued to empower you to Be The Expert in the MedTech industry. As your trusted resource for up-to-date industry insights, we delivered real-time market data, analysis and actionable insights across the orthopedics, wound care, regenerative medicine and neurotherapy markets. Here are SmartTRAK's Top Blog Posts from 2024, offering valuable perspectives from our expert analysts.
- Skin Substitute Market Rocked by DOJ Investigations
SmartTRAK believes the billions of dollars of Medicare abuse already uncovered is the tip of the iceberg in services billed to Medicare via the Physician Fee Schedule. - Medtronic: Making Waves At NANS 2024
Medtronic executives discuss how the company is making waves in interventional pain, minimally invasive spine and deep brain stimulation in an interview with SmartTRAK at NANS 2024. - Spine Market Movers to Watch in 2024
SmartTRAK highlights companies to watch as they continue their double-digit growth train with multiple catalysts for expansion in 2024.
5 min read
ASPN 2024: SmartTRAK's Interview with Tim Deer, MD
By Anne Staylor on 7/16/24 8:41 PM
ASPN Chairman Tim Deer, MD, discusses the research and innovation at ASPN 2024 and the society’s collaborative approach to improving care for patients with chronic intractable pain in an interview with SmartTRAK.
Timothy R. Deer, MD, chairman of the American Society of Pain and Neuroscience (ASPN), discusses the society's goals, its rapid growth, and how ASPN is collaborating with different stakeholders to improve patient care and offer a wider range of new and innovative treatment options for patients with chronic intractable pain. To find out more, including what’s new in neuromodulation, minimally invasive spine and regenerative medicine, listen to the following video recorded live at the ASPN 2024 Annual Conference held July 11-14, 2024 in Miami Beach, FL. A link to download the complete transcript of the interview is also provided below.
SmartTRAK: Anne Staylor here with SmartTRAK. I'm at the beautiful Fontainebleau Hotel in balmy Miami Beach, Florida at the American Society of Pain and Neuroscience Annual Conference. Today is the last day of the conference and I have the pleasure of talking with Dr. Tim Deer, the chairman of ASPN. Dr. Deer, thank you for talking with me today.
Dr. Tim Deer: Anne, thank you so much for having me. It's a great pleasure to talk to you and thank you for coming to our meeting.
Yes. Well, as you know, I think three years ago was the last time I was at your meeting, and I've had a colleague cover it who lives on the East Coast since then. Now I'm back covering the meeting and wow, has it grown exponentially since you and Dr. Sayed co-founded this meeting. I think this year, there's been a lot of energy and vibrancy around the content and in the exhibit hall and honestly, there's so much news for me to cover.
But before we get into the meeting, I thought it'd be a good idea to have you start by talking about the meeting itself, how it's grown, what the attendance has been this year, et cetera. And then what have been some of the key goals of society? And what have you and your vice chair, Dr. Sayed, been working toward as a society since you established the meeting?
8 min read
SmartTRAK Insights from the 2024 AAOS/CG Musculoskeletal Conferences
By Elise Wolf on 3/15/24 9:30 AM
SmartTRAK experts across orthopedics, sports medicine, spine and enabling technology attended this year’s 2024 Canaccord Genuity Musculoskeletal and American Academy of Orthopedic Surgeons (AAOS) annual conferences. Held from February 12-15 in San Francisco, CA, these gatherings brought together the top minds in the industry. In this post, we share some key insights and updates gleaned from these conferences, offering a glimpse into the latest trends and innovations shaping the future of orthopedic and musculoskeletal care.
- MARKET
Maxx Orthopedics*
SmartTRAK learned at AAOS 2024 that Maxx Medical is going on the offensive to grow its joint replacement business in the US and that the Company plans to launch new hip and knee products in 2024.
Paragon 28*
At AAOS 2024, Paragon 28 noted that its supply chain issues have resolved and does not expect a headwind this year. As a result, Needham believes the company can return to ~20% revenue growth in 2024.
restor3d*
Restor3d reported it currently has 157 active distribution partners calling on ~22,965 orthopedic surgeons and ~18,000 podiatrists. Management noted surgeons will bring difficult cases and from there restor3d can create additional sales opportunities. CG 2024 Musculoskeletal Conference
- REVENUES
BONESUPPORT*
BONESUPPORT highlighted the continued strength of Cerament G in North America with approximate revenues of $17.0MM in Q323 since launching in June 2023. CG 2024 Musculoskeletal Conference
OrthAlign*
At AAOS 2024, SmartTRAK learned that OrthAlign’s 2023 revenue was up +25% to $51MM, led by strong adoption of its Lantern next-generation handheld navigation system and increasing use of the Balance gap balancing feature on Lantern Knee. The company noted +37% growth in the ASC setting.
4 min read
SmartTRAK's Top 12 Blog Posts of 2023
By Thomas Wallick on 1/30/24 1:04 PM
Throughout 2023, SmartTRAK led the way in helping you Be The Expert in the MedTech industry. Serving as your trusted resource for the latest industry developments, we provided real-time market data and analysis across the orthopedic, wound care, regenerative medicine and neurotherapy sectors. Presenting SmartTRAK's Top 12 Blog Posts from 2023, featuring indispensable insights from our expert analysts.
- Could Reverse Hips Change the Total Hip Game?
Hip Innovation Technology is betting on its Reverse HRS Hip to change the practice of total hip replacement - Three Ortho Robotics Companies to Watch in 2023
SmartTRAK identifies three orthopedic robotics companies strategically positioned to shake things up this year in the fast-growing robotic-assisted TJA market. - Saluda Medical: Changing the Game in Spinal Cord Stimulation
Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK.
4 min read
SmartTRAK Announces Software Advancements & Launches Insights Reports for Emerging Orthopedic/Spine and Wound Medtech Markets
By Gabriele Nichols on 10/18/23 10:15 AM
New SaaS technology offering delivers competitive advantage in rapidly changing Ambulatory Surgery Center market.
SmartTRAK, the leading global Medtech business and market software intelligence solution in the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets, announces the release of enhanced software products and strategic reports available for purchase in Q4 to help clients position themselves for growth in 2024 and beyond.
Powered by industry experts and data analysts, SmartTRAK's Insights-as-a-Service platform is the Medtech industry's only "all-in-one" solution that delivers market insights and business intelligence via an intuitive SaaS platform. Designed to reduce the redundancies in market research, SmartTRAK compiles and curates insights from hundreds of disparate information sources into its highly valued SmartTRAK Daily Updates, comprehensive market overviews and simple-to-use tools and dashboards for market, product and financial analysis.
2 min read
A Glimpse into 2023: Regen Med Trends
By Freddy Buntoum on 3/31/23 4:04 PM
Is regenerative medicine really the way of the future? In this article, SmartTRAK looks at the macroeconomic environment going into 2023, as well as some of the latest trends, with a special focus on two segments: platelet-rich-plasma (PRP) and adipose tissue.
- PRP Trends and the Impacts to 2023 and Beyond
- Headwinds in 2023
- Trends in PRP Clinical Trials
- Anticipated 2023 US PRP Market Share Standings
- Adipose Trends and the Impacts to 2023 and Beyond
- Adipose tissue therapy gaining interest in the field of sports medicine
- Patient demand for minimally-invasive solutions
- Adipose-derived cell therapies for OA and Degenerative Disc Disease
To download and read the complete "A Glimpse into 2023: Regen Med Trends" article by Freddy Buntoum, SmartTRAK's Senior Analyst, Orthobiologics and Regenerative Medicine, just click the button below.